73 Results for "

etb

" in MedChemExpress (MCE) Product Catalog:
Products (73)

73 Results for "etb" in MCE Product Catalog:

  • Isoforms Recommended:
32
32 Publications Verification
Cat. No.: HY-A0013
CAS No.: 147536-97-8
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease Endocrinology Cancer

Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors with Ki of 4.7 nM and 95 nM in human SMC, respectively.
32
32 Publications Verification
Cat. No.: HY-A0013A
CAS No.: 157212-55-0
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease Endocrinology Cancer

Bosentan hydrate is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors with Ki of 4.7 nM and 95 nM in human SMC, respectively.
14
14 Cited Publications
Cat. No.: HY-14184
CAS No.: 441798-33-0
Pureté:  99.85%
Synonyms: ACT-064992
Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .
14
14 Cited Publications
Cat. No.: HY-15894A
CAS No.: 173326-37-9
Pureté:  98.66%
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease Endocrinology Cancer

BQ-788 is a potent, selective ETB receptor antagonist with IC50 of 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC50 of 1300 nM .
14
14 Cited Publications
Cat. No.: HY-15894
CAS No.: 156161-89-6
Pureté:  99.33%
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease Endocrinology Cancer

BQ-788 sodium salt is a potent and selective ETB receptor antagonist, inhibiting ET-1 binding to ETB receptors with an IC50 of 1.2 nM in human Girrardi heart cells .
9
9 Cited Publications
Cat. No.: HY-P0202
CAS No.: 117399-94-7
Synonyms: ET-1 (swine, human)
Target:  

Endothelin Receptor

Domaines de recherche:  

Metabolic Disease Inflammation/Immunology

Endothelin 1 (swine, human) (ET-1) is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 acts through two types of receptors ETA and ETB .
9
9 Cited Publications
Cat. No.: HY-P0202A
CAS No.: 394693-38-0
Synonyms: ET-1 (swine, human) TFA
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease

Endothelin 1 (swine, human) (ET-1) TFA is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 TFA acts through two types of receptors ETA and ETB .
3
3 Cited Publications
Cat. No.: HY-15895
CAS No.: 1103522-45-7
Pureté:  99.98%
Synonyms: ACT-132577
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease Endocrinology

Aprocitentan (ACT-132577) is the major and pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual ETA/ETB antagonist with IC50s of 3.4 nM and 987 nM, and pA2 valus of 6.7 and 5.5, respectively. Aprocitentan is an antihypertensive agent .
2
2 Cited Publications
Cat. No.: HY-11103
CAS No.: 210421-74-2
Pureté:  98.83%
Synonyms: IPI 1040 sodium; TBC11251 sodium
Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan sodium exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
2
2 Cited Publications
Cat. No.: HY-120295
CAS No.: 195529-54-5
Pureté:  99.51%
Domaines de recherche:  

Cardiovascular Disease Endocrinology

A-192621, a chemical probe, is a potent, nonpeptide, orally active and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. The selectivity of A-192621 is 636-fold higher than ETA (IC50 of 4280 nM and Ki of 5600 nM). A-192621 promotes apoptosis in PASMCs. A-192621 alos causes elevation of arterial blood pressure and an elevation in the plasma ET-1 level .
1
1 Cited Publications
Cat. No.: HY-10088
CAS No.: 186497-07-4
Pureté:  99.37%
Synonyms: ZD4054
Domaines de recherche:  

Endocrinology Cancer

Zibotentan (ZD4054) is a potent, selective and orally active endothelin A (ETA) receptor antagonist with a Ki of 13 nM. Zibotentan has no inhibitory effect on ETB. Zibotentan has anticancer effects and can be used for castration-resistant prostate cancer (CRPC) research .
1
1 Cited Publications
Cat. No.: HY-16465
CAS No.: 142569-99-1
Target:  

Endothelin Receptor

Domaines de recherche:  

Neurological Disease Endocrinology

IRL-1620 is a potent and selective endothelin receptor type B (ETB) agonist with a Ki of 16 pM.
1
1 Cited Publications
Cat. No.: HY-114367
CAS No.: 15674-58-5
Pureté:  98.83%
Synonyms: Delphinidin 3-O-rutinoside chloride
Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ETB receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes .
1
1 Cited Publications
Cat. No.: HY-16465A
IRL-1620 (TFA) is a potent and selective endothelin receptor type B (ETB) agonist with a Ki of 16 pM .
Cat. No.: HY-15895S
CAS No.: 2748196-51-0
Synonyms: ACT-132577-d4
Aprocitentan-d4 is a deuterium labeled Aprocitentan. Aprocitentan is a major and pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual ETA/ETB antagonist with IC50s of 3.4 nM and 987 nM, and pA2 valus of 6.7 and 5.5, respectively. Aprocitentan is an antihypertensive agent .
Cat. No.: HY-103460
CAS No.: 169545-27-1
Pureté:  99.27%
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease

IRL 2500 is a potent Endothelin receptor antagonist. IRL 2500 shows IC50 values of 1.3 and 94 nM for ETB and ETA receptors, respectively. IRL 2500 inhibits ETB receptor-mediated blood pressure increase and renal vascular resistance in rats in vivo .
Cat. No.: HY-17351
CAS No.: 180384-57-0
Synonyms: RO 610612
Tezosentan (RO 610612) is an endothelin (ET) receptor antagonist, with pA2s of 9.5, 7.7 for ETA and ETB receptors, respectively.
Cat. No.: HY-15195
CAS No.: 290815-26-8
Pureté:  98.15%
Synonyms: Ro 67-0565; SPP-301
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease Endocrinology

Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure .
Cat. No.: HY-19431
CAS No.: 175556-12-4
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease

Ro 46-8443 is the first non-peptide endothelin ETB receptor selective antagonist. Ro 46-8443 displays an at least 100-fold selectivity for ETB (IC50: 34-69 nM) over ETA receptors (IC50: 6800 nM) .
Cat. No.: HY-15404
CAS No.: 171714-84-4
Pureté:  98.67%
Synonyms: Lu-135252
Target:  

Endothelin Receptor

Domaines de recherche:  

Cardiovascular Disease Endocrinology

Darusentan (Lu-135252) is a selective endothelin receptor A (ET-A) receptor antagonist, which binds with a Ki of 1.4 nM to the ET-A receptor and a Ki of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors . Darusentan competes for radiolabeled endothelin binding in rat aortic vascular smooth muscle cells (RAVSMs) membranes with single-site kinetics, exhibiting a Ki of 13 nM .